New SCHWIND LASIK platform going strong at 6 months

Article

Six-month data for myopia treatments with the SCHWIND AMARIS laser show that it is effective and patient friendly.

Six-month data for myopia treatments with the SCHWIND AMARIS laser show that it is effective and patient friendly.

The multi-centric LASIK myopia study, conducted by Maria-Clara Arbelaez and colleagues, enrolled 358 eyes. Of all the eyes, 65% achieved a postoperative uncorrected visual acuity (UCVA) of 20/16 or better and 98% achieved a UCVA of 20/20 or better. Target refraction was also found to be good, with 96% of treated eyes falling into the ±0.5 D range.

Aberration-free treatments were also found to be very safe. More than 55% of eyes gained one or more lines of visual acuity after six months and the induction of higher order aberrations, compared with non-aspheric treatment, was minimal. The total RMS of postoperative higher order aberrations (for 6 mm analysis diameter) rose by an average of just 0.07 µm. This also resulted in higher contrast sensitivity for patients.

Importantly, good results were seen very shortly after treatment, with study participants attaining the same visual acuity as the preoperative best corrected vision just one day after the procedure.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.